BR112019025402A2 - Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso - Google Patents

Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso Download PDF

Info

Publication number
BR112019025402A2
BR112019025402A2 BR112019025402-1A BR112019025402A BR112019025402A2 BR 112019025402 A2 BR112019025402 A2 BR 112019025402A2 BR 112019025402 A BR112019025402 A BR 112019025402A BR 112019025402 A2 BR112019025402 A2 BR 112019025402A2
Authority
BR
Brazil
Prior art keywords
bont
toxin
skin
melanin
neurotoxin
Prior art date
Application number
BR112019025402-1A
Other languages
English (en)
Portuguese (pt)
Inventor
P.S. Jacky Birgitte
Birgitte P.S. Jacky
Z. Malik Shizazh
Shizazh Z. Malik
Wang Joanne
Joanne Wang
Liu Yi
Yi Liu
Brideau-Andersen Amy
Amy BRIDEAU-ANDERSEN
E. Steward Lance
Lance E. Steward
Q. Le Linh
Linh Q. Le
C. Hsia Edward
Edward C. Hsia
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of BR112019025402A2 publication Critical patent/BR112019025402A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
BR112019025402-1A 2017-05-31 2018-05-30 Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso BR112019025402A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512792P 2017-05-31 2017-05-31
US62/512,792 2017-05-31
PCT/US2018/035025 WO2018222652A1 (en) 2017-05-31 2018-05-30 Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Publications (1)

Publication Number Publication Date
BR112019025402A2 true BR112019025402A2 (pt) 2020-06-23

Family

ID=62683456

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025402-1A BR112019025402A2 (pt) 2017-05-31 2018-05-30 Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso

Country Status (16)

Country Link
US (3) US10912823B2 (https=)
EP (1) EP3630298A1 (https=)
JP (1) JP7096845B2 (https=)
KR (1) KR20200011499A (https=)
CN (1) CN110891594A (https=)
AU (1) AU2018277754A1 (https=)
BR (1) BR112019025402A2 (https=)
CA (1) CA3065542A1 (https=)
CL (1) CL2019003484A1 (https=)
CO (1) CO2019014592A2 (https=)
IL (1) IL270986B (https=)
MX (1) MX2019014349A (https=)
PH (1) PH12019502721A1 (https=)
RU (1) RU2019143639A (https=)
WO (1) WO2018222652A1 (https=)
ZA (1) ZA201907916B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
KR20210097530A (ko) * 2020-01-30 2021-08-09 (주)메디톡스 Snare 복합체의 형성을 저해하는 펩티드, 및 그의 용도
KR102550756B1 (ko) * 2022-12-21 2023-07-05 (주)메디톡스 세포로부터 신경전달물질 분비를 저해하는 펩티드, 및 그의 용도
CN121511091A (zh) 2023-07-12 2026-02-10 莫茨药物股份两合公司 通过肉毒杆菌毒素的色素沉着过度病况治疗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
KR20050094817A (ko) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
GB0820970D0 (en) * 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20120195878A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US20140276359A1 (en) * 2013-03-15 2014-09-18 Plum Systems Co. Apparatus and method for tissue rejuvenation
AU2014301116B2 (en) * 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
CN105683212B (zh) * 2013-08-21 2020-03-17 香港理工大学 高催化活性的基因改造梭菌属神经毒素
WO2016048689A1 (en) * 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
MX2019005833A (es) * 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
BR112019025402A2 (pt) * 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
AU2018389104A1 (en) * 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Also Published As

Publication number Publication date
IL270986B (en) 2021-07-29
JP2020522492A (ja) 2020-07-30
US20210162027A1 (en) 2021-06-03
AU2018277754A1 (en) 2020-01-02
RU2019143639A (ru) 2021-06-30
US20230302103A1 (en) 2023-09-28
PH12019502721A1 (en) 2020-10-19
KR20200011499A (ko) 2020-02-03
CL2019003484A1 (es) 2020-05-15
EP3630298A1 (en) 2020-04-08
US20180344820A1 (en) 2018-12-06
ZA201907916B (en) 2021-05-26
WO2018222652A1 (en) 2018-12-06
CO2019014592A2 (es) 2020-06-09
MX2019014349A (es) 2020-07-28
JP7096845B2 (ja) 2022-07-06
CN110891594A (zh) 2020-03-17
IL270986A (en) 2020-01-30
RU2019143639A3 (https=) 2021-09-06
CA3065542A1 (en) 2018-12-06
US10912823B2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
US20230302103A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
KR101041698B1 (ko) 경피성 보툴리눔 독소 조성물
ES2761664T3 (es) Entrega dérmica
US10245305B2 (en) Botulinum toxin therapy for skin disorders
BR112020012641A2 (pt) polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
BR112016027773B1 (pt) Proteína recombinante célula-penetrante de toxina botulínica,composição farmacêutica, composição para um agente dérmico externo e composição cosmética
JP2018184460A (ja) 注射用ボツリヌス毒素製剤
CN102988995A (zh) 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
BR112020020346A2 (pt) Neurotoxinas para uso na inibição de cgrp
MX2011010335A (es) Metodos y composiciones para tratar afecciones de la piel asociadas con hiperreactividad vascular.
US20170361130A9 (en) Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
Johnston Anatomy and physiology of the oral mucosa
AU2021221835A1 (en) Cosmetic base solutions as cosmetic delivery systems, associated cosmetic formulations, and uses thereof
PT1853303E (pt) Composições estabilizadas para administração tópica, e métodos para a sua preparação
KR20210093748A (ko) 흉터형성을 최소화하는 데에 사용하기 위한 신경독소
US20060293227A1 (en) Cosmetic compositions and methods using transforming growth factor-beta mimics
US20240228536A1 (en) Peptides for use in skin and hair pigmentation
KR20260035809A (ko) 보툴리눔 독소에 의한 과색소침착 상태의 치료
BR112020023071A2 (pt) método de distribuição de agentes biológicos a partir de uma formulação tópica
KR20220161685A (ko) 점막미백주사액 및 그 제조방법
BR102016022420A2 (pt) Composição tópica, uso cosmético da composição e composição tópica e dermatológica
BR102016022422A2 (pt) Composição despigmentante para aplicação tópica
BRPI1014922B1 (pt) Uso de uma composição tópica, emplastro para pele e kit para tratar o distúrbio da pele
BR102016022421A2 (pt) Método para melhorar a penetração na pele de um agente farmacologicamente ativo, método para entregar ativos à interface de junção derme- epiderme e processo para o tratamento das camadas superiores da epiderme
HK1182648A (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived form hiv-tat

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements